Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio
Sight Sciences (SGHT) has announced the launch of OMNI® Edge Surgical System, expanding its OMNI® product portfolio. The new system will debut at the 2025 ASCRS Annual Meeting in Los Angeles.
The OMNI Edge features TruSync™ technology and increased viscoelastic capacity of 21 µL, nearly double the previous 11 µL capacity. The system is designed for minimally invasive glaucoma surgery (MIGS) and treats all three resistance areas in the aqueous outflow system: trabecular meshwork, Schlemm's canal, and collector channels.
The device maintains the trusted safety and usability of the original OMNI system while introducing synchronized viscoelastic delivery with surgeon rotation. It can be used as a standalone procedure or combined with cataract surgery for primary open-angle glaucoma (POAG) treatment. With over 300,000 procedures performed, OMNI has established itself as a leader in canal-based MIGS.
Sight Sciences (SGHT) ha annunciato il lancio del OMNI® Edge Surgical System, ampliando la sua gamma di prodotti OMNI®. Il nuovo sistema sarà presentato al Congresso Annuale ASCRS 2025 a Los Angeles.
Il OMNI Edge è dotato della tecnologia TruSync™ e di una capacità viscoelastica aumentata a 21 µL, quasi il doppio rispetto agli 11 µL precedenti. Il sistema è progettato per la chirurgia minimamente invasiva del glaucoma (MIGS) e tratta tutte e tre le aree di resistenza nel sistema di deflusso dell’umore acqueo: la trabecolato, il canale di Schlemm e i canali collettori.
Il dispositivo mantiene la sicurezza e la facilità d’uso del sistema OMNI originale, introducendo la somministrazione sincronizzata del viscoelastico con la rotazione del chirurgo. Può essere utilizzato come procedura autonoma o in combinazione con la chirurgia della cataratta per il trattamento del glaucoma primario ad angolo aperto (POAG). Con oltre 300.000 interventi eseguiti, OMNI si è affermato come leader nella MIGS basata sul canale.
Sight Sciences (SGHT) ha anunciado el lanzamiento del OMNI® Edge Surgical System, expandiendo su portafolio de productos OMNI®. El nuevo sistema debutará en la Reunión Anual ASCRS 2025 en Los Ángeles.
El OMNI Edge cuenta con la tecnología TruSync™ y una capacidad viscoelástica aumentada de 21 µL, casi el doble de la capacidad previa de 11 µL. El sistema está diseñado para cirugía mínimamente invasiva del glaucoma (MIGS) y trata las tres áreas de resistencia en el sistema de drenaje del humor acuoso: la malla trabecular, el canal de Schlemm y los canales colectores.
El dispositivo mantiene la seguridad y facilidad de uso confiables del sistema OMNI original, introduciendo la entrega sincronizada de viscoelástico con la rotación del cirujano. Puede usarse como procedimiento independiente o combinado con cirugía de cataratas para el tratamiento del glaucoma primario de ángulo abierto (POAG). Con más de 300,000 procedimientos realizados, OMNI se ha consolidado como líder en MIGS basada en el canal.
Sight Sciences (SGHT)는 OMNI® Edge Surgical System의 출시를 발표하며 OMNI® 제품 포트폴리오를 확장했습니다. 새 시스템은 2025년 로스앤젤레스에서 열리는 ASCRS 연례회의에서 처음 공개됩니다.
OMNI Edge는 TruSync™ 기술과 이전 11 µL 용량의 거의 두 배인 21 µL의 증가된 점탄성 용량을 특징으로 합니다. 이 시스템은 최소 침습 녹내장 수술(MIGS)을 위해 설계되었으며, 방수 유출 시스템의 세 가지 저항 부위인 섬유주, 슐렘관, 수집관을 모두 치료합니다.
이 장치는 원래 OMNI 시스템의 신뢰할 수 있는 안전성과 사용 편의성을 유지하면서 외과의사의 회전에 맞춘 동기화된 점탄성 물질 전달을 도입합니다. 단독 시술로 사용하거나 백내장 수술과 병행하여 원발 개방각 녹내장(POAG) 치료에 사용할 수 있습니다. 30만 건이 넘는 시술을 통해 OMNI는 관 기반 MIGS 분야의 선두주자로 자리매김했습니다.
Sight Sciences (SGHT) a annoncé le lancement du OMNI® Edge Surgical System, élargissant ainsi sa gamme de produits OMNI®. Le nouveau système sera présenté lors de la réunion annuelle ASCRS 2025 à Los Angeles.
L’OMNI Edge est équipé de la technologie TruSync™ et d’une capacité viscoélastique accrue de 21 µL, soit presque le double de la capacité précédente de 11 µL. Le système est conçu pour la chirurgie mini-invasive du glaucome (MIGS) et traite les trois zones de résistance du système d’écoulement de l’humeur aqueuse : le trabéculum, le canal de Schlemm et les canaux collecteurs.
Le dispositif conserve la sécurité et la facilité d’utilisation éprouvées du système OMNI original tout en introduisant une distribution synchronisée du viscoélastique avec la rotation du chirurgien. Il peut être utilisé en procédure autonome ou combiné à la chirurgie de la cataracte pour le traitement du glaucome primaire à angle ouvert (POAG). Avec plus de 300 000 interventions réalisées, OMNI s’est imposé comme un leader dans le MIGS basé sur le canal.
Sight Sciences (SGHT) hat die Einführung des OMNI® Edge Surgical System bekannt gegeben und erweitert damit sein OMNI®-Produktportfolio. Das neue System wird auf der ASCRS-Jahrestagung 2025 in Los Angeles vorgestellt.
Das OMNI Edge verfügt über die TruSync™-Technologie und eine erhöhte viskoelastische Kapazität von 21 µL, fast doppelt so viel wie die bisherige Kapazität von 11 µL. Das System ist für minimalinvasive Glaukomchirurgie (MIGS) konzipiert und behandelt alle drei Widerstandsbereiche im Kammerwasserabfluss: das Trabekelmaschenwerk, den Schlemm-Kanal und die Sammelkanäle.
Das Gerät bewahrt die bewährte Sicherheit und Benutzerfreundlichkeit des ursprünglichen OMNI-Systems und führt gleichzeitig eine synchronisierte Abgabe des Viskoelastikums mit der Rotation des Chirurgen ein. Es kann als eigenständiges Verfahren oder in Kombination mit der Kataraktchirurgie zur Behandlung des primären Offenwinkelglaukoms (POAG) eingesetzt werden. Mit über 300.000 durchgeführten Eingriffen hat sich OMNI als führend im kanalbasierten MIGS etabliert.
- Launch of new OMNI Edge system with enhanced features and doubled viscoelastic capacity
- Proven track record with over 300,000 procedures performed
- Versatile application for both standalone and combination procedures
- Maintains availability of original OMNI system, expanding product portfolio
- availability - only available in the United States
Insights
Sight Sciences' OMNI Edge advances glaucoma surgery with doubled viscoelastic capacity and synchronized delivery technology.
The launch of the OMNI® Edge Surgical System represents a strategic expansion of Sight Sciences' MIGS (minimally invasive glaucoma surgery) portfolio. The new system offers notable technical improvements over the original OMNI, including nearly doubled viscoelastic capacity (21 µL vs. 11 µL) and TruSync™ technology that synchronizes viscoelastic deployment with surgeon control movements.
From a clinical perspective, these advancements directly address procedural precision in comprehensive MIGS. The enhanced viscoelastic delivery system allows for more consistent treatment of all three known resistance areas in the aqueous outflow system: trabecular meshwork, Schlemm's canal, and collector channels. This comprehensive, implant-free approach provides versatility across varying stages of primary open-angle glaucoma.
What's particularly valuable is the system's dual utility as both a standalone procedure and as a complement to cataract surgery. The company reports the original OMNI platform has been used in over 300,000 procedures, suggesting established clinical acceptance. Early clinical feedback from Dr. Christine Funke highlights improved predictability and ergonomics, though comprehensive clinical data specific to OMNI Edge is not yet presented.
By maintaining both the original OMNI alongside the new Edge version, Sight Sciences is effectively addressing different surgical preferences while building on their established canal-based MIGS technology. This product evolution follows a logical advancement path by enhancing key performance features while preserving the trusted handling characteristics surgeons have become familiar with.
New system features higher viscoelastic capacity and TruSync™ technology, engineered to safely synchronize surgical control and precision in implant-free, comprehensive MIGS
MENLO PARK, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) , an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the expansion of the OMNI® product family by launching the OMNI® Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, taking place April 25–27 in Los Angeles, California.
OMNI Edge with TruSync™ technology builds on the proven performance of the OMNI® Surgical System and introduces a higher-capacity viscoelastic delivery feature (21 µL) while maintaining the trusted safety, efficacy, and usability of the OMNI device. Designed for versatility in minimally invasive glaucoma surgery (MIGS), OMNI Edge reduces intraocular pressure (IOP) by treating all three known areas of resistance in the aqueous outflow system—the trabecular meshwork, Schlemm’s canal, and the collector channels. The system is adaptable to all stages of primary open-angle glaucoma (POAG) and can be used as a standalone procedure or in combination with cataract surgery.
"OMNI Edge represents the next step in providing the most comprehensive and versatile implant-free MIGS technology. The higher viscoelastic capacity, ergonomics, and predictability enhance my ability to safely and comprehensively treat a wide range of primary open-angle glaucoma cases,” said Christine Funke, MD, following early clinical use.
Key features of OMNI Edge:
- TruSync technology: A patented viscoelastic delivery technology synchronized with surgeon rotation of the control wheel — enabling consistent, predictable, and reproducible viscoelastic deployment along every clock hour of Schlemm’s canal that is treated.
- Expanded viscoelastic capacity: Delivers up to 21 µL—nearly double the 11 µL capacity of the OMNI Surgical System — with precise control, while maintaining the trusted ergonomics, safety, and versatility of the OMNI Surgical System.
- Trusted ergonomics: Retains the intuitive design of the OMNI Surgical System, preserving the intuitive handling surgeons know and trust, enabling a seamless adoption.
"Sight Sciences remains dedicated to evolving glaucoma care with interventional technologies that align with the way surgeons treat their patients safely, efficiently, and comprehensively," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "OMNI Edge is a testament to our commitment to innovation and ongoing collaboration with the ophthalmic community."
Multiple studies, including prospective, long-term, and real-world have demonstrated the safety, effectiveness, and durability of the OMNI procedure in both standalone and combination cataract procedures. With over 300,000 procedures performed,1 OMNI has established itself as a leader in canal-based MIGS.
The introduction of OMNI Edge expands the OMNI product family while maintaining the availability of OMNI, ensuring surgeons have access to both technologies to meet their unique surgical preferences and patient needs. OMNI Edge is only available in the United States.
Experience OMNI Edge at ASCRS 2025
Join us in celebrating the launch of OMNI Edge at the ASCRS meeting in Los Angeles on April 26, 2025, from 4:00 pm to 5:00 pm PT at our booth (#2439). Attendees are invited to explore this latest innovation and enjoy an hour networking with leading physicians and industry leaders. RSVP and learn more at sightsciences.com/ascrs.
About the OMNI Edge Surgical System
The OMNI® Edge Surgical System technology consists of a handheld, single-use therapeutic device for minimally invasive glaucoma surgery (MIGS). OMNI Edge allows surgeons 360 degrees of customized intervention to address the three primary areas of resistance of an eye’s diseased conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) through a single clear corneal microincision.
OMNI Edge is indicated for canaloplasty (the microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Visit omnisurgical.com/instructionsforuse to access the instructions for use, warnings, precautions, and adverse event information. OMNI Edge should not be used in any situations where the iridocorneal angle is compromised or has been damaged since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris or in quadrants with previous MIGS implants. OMNI technology is protected by a global patent portfolio including 32 issued patents worldwide. For more information, to schedule a demonstration, or to request training, visit sightsciences.com/omniedge.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Visit www.sightsciences.com for more information.
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, without limitation statements regarding launch of the Company’s OMNI® Edge Surgical System. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
1 Estimate based on units of OMNI (and predicates) shipped as of December 31, 2024.
© 2025 Sight Sciences. All rights reserved. Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. TruSync is a trademark of Sight Sciences. 04/2025 OM-3441-US.v1
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f19dcae-7168-4dbc-b744-9c40fac4256d
FAQ
What are the key features of Sight Sciences' new OMNI Edge Surgical System (SGHT)?
How many procedures have been performed with the OMNI Surgical System (SGHT)?
When will Sight Sciences (SGHT) launch the OMNI Edge Surgical System?
What conditions can the OMNI Edge Surgical System (SGHT) treat?
